Dakota Wealth Management Has $11.32 Million Stock Holdings in Cencora, Inc. $COR

Dakota Wealth Management decreased its position in shares of Cencora, Inc. (NYSE:COR) by 3.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 37,756 shares of the company’s stock after selling 1,258 shares during the period. Dakota Wealth Management’s holdings in Cencora were worth $11,321,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Voleon Capital Management LP bought a new position in shares of Cencora in the first quarter worth $3,111,000. Exchange Traded Concepts LLC increased its position in shares of Cencora by 4.5% in the first quarter. Exchange Traded Concepts LLC now owns 1,104 shares of the company’s stock worth $307,000 after purchasing an additional 48 shares during the period. Focus Partners Wealth increased its position in shares of Cencora by 25.8% in the first quarter. Focus Partners Wealth now owns 5,715 shares of the company’s stock worth $1,589,000 after purchasing an additional 1,171 shares during the period. Integrated Wealth Concepts LLC increased its position in shares of Cencora by 42.5% in the first quarter. Integrated Wealth Concepts LLC now owns 8,008 shares of the company’s stock worth $2,227,000 after purchasing an additional 2,389 shares during the period. Finally, Ascent Group LLC increased its position in shares of Cencora by 42.7% in the first quarter. Ascent Group LLC now owns 12,586 shares of the company’s stock worth $3,500,000 after purchasing an additional 3,764 shares during the period. Institutional investors own 97.52% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on COR shares. Jefferies Financial Group lifted their target price on Cencora from $275.00 to $300.00 and gave the company a “hold” rating in a research report on Monday, June 30th. Wells Fargo & Company lifted their target price on Cencora from $337.00 to $354.00 and gave the company an “overweight” rating in a research report on Wednesday, August 13th. Finally, Morgan Stanley set a $330.00 target price on Cencora and gave the company an “equal weight” rating in a research report on Wednesday, July 16th. Nine equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, Cencora currently has a consensus rating of “Moderate Buy” and an average price target of $311.25.

Cencora Price Performance

Cencora stock opened at $308.33 on Thursday. The stock’s 50 day moving average is $292.62 and its 200 day moving average is $287.78. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53. The firm has a market cap of $59.78 billion, a P/E ratio of 31.72, a P/E/G ratio of 1.54 and a beta of 0.62. Cencora, Inc. has a one year low of $218.65 and a one year high of $309.64.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $4.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.79 by $0.21. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The firm had revenue of $80.66 billion for the quarter, compared to analyst estimates of $80.34 billion. During the same period in the previous year, the firm earned $3.34 earnings per share. The company’s revenue was up 8.7% compared to the same quarter last year. As a group, research analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Friday, August 15th were issued a dividend of $0.55 per share. The ex-dividend date was Friday, August 15th. This represents a $2.20 annualized dividend and a yield of 0.7%. Cencora’s dividend payout ratio is 22.63%.

Insider Buying and Selling at Cencora

In other Cencora news, Chairman Steven H. Collis sold 31,350 shares of the company’s stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the transaction, the chairman owned 305,913 shares in the company, valued at $88,671,942.18. This represents a 9.30% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Robert P. Mauch sold 5,097 shares of the company’s stock in a transaction on Thursday, September 18th. The shares were sold at an average price of $290.00, for a total value of $1,478,130.00. Following the transaction, the chief executive officer directly owned 39,274 shares in the company, valued at $11,389,460. This represents a 11.49% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 55,993 shares of company stock valued at $16,292,923 in the last quarter. 10.80% of the stock is currently owned by corporate insiders.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.